Evidence map›Paper›PMID 35642525›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2023

Maternal Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccination During Pregnancy: Impact on Infant Anti-Pertussis Antibody Concentrations by Maternal Pertussis Priming Series.

Fiona P Havers, Tami H Skoff, Marcia A Rench, Monica Epperson, Gowrisankar Rajam, Jarad Schiffer, Susan Hariri, Laurie S Swaim, Carol J Baker, C Mary Healy

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Fiona P HaversDivision of Bacterial Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID 0000-0001-9873-6195
Tami H SkoffDivision of Bacterial Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Marcia A RenchDepartment of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.
Monica EppersonDivision of Bacterial Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Gowrisankar RajamDivision of Bacterial Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Jarad SchifferDivision of Bacterial Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Susan HaririDivision of Bacterial Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Laurie S SwaimDepartment of Obstetrics and Gynecology, Baylor College of Medicine, Houston, Texas, USA.
Carol J BakerDepartment of Pediatrics, University of Texas Health Sciences Center at Houston, Houston, Texas, USA.
C Mary HealyDepartment of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.
Centers for Disease Control and Prevention · USBaylor College of Medicine · USThe University of Texas Health Science Center at Houston · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAcellular pertussis (aP) vaccines replaced whole-cell pertussis (wP) vaccines for the US childhood primary series in 1997. As women primed with aP vaccines enter childbearing age, protection of infants through tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccination during pregnancy may be impacted.

methodsTerm infants born to women vaccinated with Tdap during pregnancy were included. Geometric mean concentrations (GMCs) of pertussis-specific immunoglobulin G antibodies (international units per milliliter) in cord blood of infants born to women born after 1997 (aP-primed) were compared with those born to women born before 1992 (wP-primed).

results253 and 506 infants born to aP- and wP-primed women, respectively, were included. Compared with wP-primed women, aP-primed women were younger, more likely to be Hispanic or non-Hispanic Black, and had lower-birthweight infants (P < .01 for all). Antibodies against pertussis toxin (PT) and filamentous hemagglutinin (FHA) were lower among infants born to aP-primed vs wP-primed women (PT, 17.3 vs 36.4; GMC ratio, .475; 95% confidence interval [CI], .408-.552 and FHA, 104.6 vs 121.4; GMC ratio, 0.861; 95% CI, .776-.958). No differences were observed for anti-fimbriae or anti-pertactin antibodies.

conclusionsTransplacental anti-pertussis antibody concentrations in infants of women vaccinated with Tdap during pregnancy differed by type of childhood vaccine the women received. Notably, anti-PT antibody levels, considered most important in preventing severe infant disease, were lower in infants born to aP-primed vs wP-primed women. Maternal Tdap vaccination may confer less protection against pertussis in infants born to aP-primed vs those born to wP-primed women.

Indexed as

DiphtheriaDiphtheria-Tetanus-acellular Pertussis VaccinesWhooping CoughAntibodies, BacterialFemaleHumansInfantPertussis ToxinPertussis VaccinePregnancyVaccinationAntibodies, BacterialDiphtheria-Tetanus-acellular Pertussis VaccinesPertussis ToxinPertussis Vaccineinfantsmaternal immunizationpertussispregnancyTdap

Identifiers

PMID35642525
OpenAlexW4281856663

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.